These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 31831473)

  • 1. Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA
    Ruiz de Adana MS; Alhambra-Expósito MR; Muñoz-Garach A; Gonzalez-Molero I; Colomo N; Torres-Barea I; Aguilar-Diosdado M; Carral F; Serrano M; Martínez-Brocca MA; Duran A; Palomares R;
    Diabetes Care; 2020 Feb; 43(2):337-342. PubMed ID: 31831473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
    Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
    Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficiency of telemedicine to optimize metabolic control in patients with type 1 diabetes mellitus: Telemed study.
    Esmatjes E; Jansà M; Roca D; Pérez-Ferre N; del Valle L; Martínez-Hervás S; Ruiz de Adana M; Linares F; Batanero R; Vázquez F; Gomis R; de Solà-Morales O;
    Diabetes Technol Ther; 2014 Jul; 16(7):435-41. PubMed ID: 24528195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.
    Lind M; Polonsky W; Hirsch IB; Heise T; Bolinder J; Dahlqvist S; Schwarz E; Ólafsdóttir AF; Frid A; Wedel H; Ahlén E; Nyström T; Hellman J
    JAMA; 2017 Jan; 317(4):379-387. PubMed ID: 28118454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.
    Bergenstal RM; Johnson M; Passi R; Bhargava A; Young N; Kruger DF; Bashan E; Bisgaier SG; Isaman DJM; Hodish I
    Lancet; 2019 Mar; 393(10176):1138-1148. PubMed ID: 30808512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact and duration effect of telemonitoring on ΗbA1c, BMI and cost in insulin-treated Diabetes Mellitus patients with inadequate glycemic control: A randomized controlled study.
    Fountoulakis S; Papanastasiou L; Gryparis A; Markou A; Piaditis G
    Hormones (Athens); 2015; 14(4):632-43. PubMed ID: 26188234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
    Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
    Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study.
    Charleer S; De Block C; Nobels F; Radermecker RP; Lowyck I; Mullens A; Scarnière D; Spincemaille K; Strivay M; Weber E; Taes Y; Vercammen C; Keymeulen B; Mathieu C; Gillard P;
    Diabetes Care; 2020 Dec; 43(12):3016-3023. PubMed ID: 33067260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study).
    Charpentier G; Benhamou PY; Dardari D; Clergeot A; Franc S; Schaepelynck-Belicar P; Catargi B; Melki V; Chaillous L; Farret A; Bosson JL; Penfornis A;
    Diabetes Care; 2011 Mar; 34(3):533-9. PubMed ID: 21266648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG
    BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial.
    Hermanides J; Nørgaard K; Bruttomesso D; Mathieu C; Frid A; Dayan CM; Diem P; Fermon C; Wentholt IM; Hoekstra JB; DeVries JH
    Diabet Med; 2011 Oct; 28(10):1158-67. PubMed ID: 21294770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial comparing a telemedicine therapeutic intervention with routine care in adults with type 1 diabetes mellitus treated by insulin pumps.
    Yaron M; Sher B; Sorek D; Shomer M; Levek N; Schiller T; Gaspar M; Frumkin Ben-David R; Mazor-Aronovitch K; Tish E; Shapira Y; Pinhas-Hamiel O
    Acta Diabetol; 2019 Jun; 56(6):667-673. PubMed ID: 30783823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes.
    Yaron M; Roitman E; Aharon-Hananel G; Landau Z; Ganz T; Yanuv I; Rozenberg A; Karp M; Ish-Shalom M; Singer J; Wainstein J; Raz I
    Diabetes Care; 2019 Jul; 42(7):1178-1184. PubMed ID: 31036546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring (HypoCOMPaSS).
    Little SA; Leelarathna L; Walkinshaw E; Tan HK; Chapple O; Lubina-Solomon A; Chadwick TJ; Barendse S; Stocken DD; Brennand C; Marshall SM; Wood R; Speight J; Kerr D; Flanagan D; Heller SR; Evans ML; Shaw JA
    Diabetes Care; 2014 Aug; 37(8):2114-22. PubMed ID: 24854041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effective use of telemedicine and self-monitoring of blood glucose via Diabetes Tele Management System (DTMS) to achieve target glycosylated hemoglobin values without serious symptomatic hypoglycemia in 1,000 subjects with type 2 diabetes mellitus--a retrospective study.
    Kesavadev J; Shankar A; Pillai PB; Krishnan G; Jothydev S
    Diabetes Technol Ther; 2012 Sep; 14(9):772-6. PubMed ID: 22734662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.